During a luncheon at the recent JPMorgan Healthcare conference in San Francisco, more than 500 institutional investors were asked to predict the fate of Bristol-Myers Squibb.
The New York-based drug giant is locked in patent litigation with a company that makes a generic version of Bristol's $3-billion-a-year anti-clotting drug Plavix, a debacle that contributed to the firing of CEO Peter R. Dolan in September.
Using electronic keypads at their tables, 60% of the attendees forecast that if Bristol prevails in the case, which goes to court on Jan. 22 in New York, another pharmaceutical maker will buy it within a year.
No comments:
Post a Comment